289 related articles for article (PubMed ID: 30003238)
41. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.
Katki HA; Kovalchik SA; Petito LC; Cheung LC; Jacobs E; Jemal A; Berg CD; Chaturvedi AK
Ann Intern Med; 2018 Jul; 169(1):10-19. PubMed ID: 29800127
[TBL] [Abstract][Full Text] [Related]
42. Selecting High-Risk Individuals for Lung Cancer Screening: A Prospective Evaluation of Existing Risk Models and Eligibility Criteria in the German EPIC Cohort.
Li K; Hüsing A; Sookthai D; Bergmann M; Boeing H; Becker N; Kaaks R
Cancer Prev Res (Phila); 2015 Sep; 8(9):777-85. PubMed ID: 26076698
[TBL] [Abstract][Full Text] [Related]
43. The Role of Change Rates of CYFRA21-1 and CEA in Predicting Chemotherapy Efficacy for Non-Small-Cell Lung Cancer.
Zhao T; Mao G; Chen M
Comput Math Methods Med; 2021; 2021():1951364. PubMed ID: 34603482
[TBL] [Abstract][Full Text] [Related]
44. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
[TBL] [Abstract][Full Text] [Related]
45. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
Seemann MD; Beinert T; Fürst H; Fink U
Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
[TBL] [Abstract][Full Text] [Related]
46. The Combination of CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer.
Wang CF; Peng SJ; Liu RQ; Yu YJ; Ge QM; Liang RB; Li QY; Li B; Shao Y
Dis Markers; 2020; 2020():8850873. PubMed ID: 33376560
[TBL] [Abstract][Full Text] [Related]
47. Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer.
He CZ; Zhang KH; Li Q; Liu XH; Hong Y; Lv NH
BMC Gastroenterol; 2013 May; 13():87. PubMed ID: 23672279
[TBL] [Abstract][Full Text] [Related]
48. [The diagnostic significance of single or combination lung cancer-related serum biomarkers in high risk lung cancer patients].
Ni J; Guo Z; Zhang L
Zhonghua Nei Ke Za Zhi; 2016 Jan; 55(1):25-30. PubMed ID: 26796649
[TBL] [Abstract][Full Text] [Related]
49. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
50. A model based on the quantification of complement C4c, CYFRA 21-1 and CRP exhibits high specificity for the early diagnosis of lung cancer.
Ajona D; Remirez A; Sainz C; Bertolo C; Gonzalez A; Varo N; Lozano MD; Zulueta JJ; Mesa-Guzman M; C Martin A; Perez-Palacios R; Perez-Gracia JL; Massion PP; Montuenga LM; Pio R
Transl Res; 2021 Jul; 233():77-91. PubMed ID: 33618009
[TBL] [Abstract][Full Text] [Related]
51. Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma.
Kao CH; Hsieh JF; Ho YJ; Ding HJ
Lung; 1999; 177(5):333-7. PubMed ID: 10467024
[TBL] [Abstract][Full Text] [Related]
52. [Clinical Significance of Tumor Marker Detection in Patients
with Advanced Squamous Cell Carcimoma of the Lung].
Liang P; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):641-647. PubMed ID: 27760591
[TBL] [Abstract][Full Text] [Related]
53. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
54. A novel model for extrapleural cavity metastasis assessment in patients with lung cancer.
Wang L; Zhao Q; Wang J; Wang T; Sun L; Chen Q; Li J; Zeng F
Biomark Med; 2021 Apr; 15(6):389-399. PubMed ID: 33709781
[No Abstract] [Full Text] [Related]
55. Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan.
Wu X; Wen CP; Ye Y; Tsai M; Wen C; Roth JA; Pu X; Chow WH; Huff C; Cunningham S; Huang M; Wu S; Tsao CK; Gu J; Lippman SM
Sci Rep; 2016 Nov; 6():36482. PubMed ID: 27805040
[TBL] [Abstract][Full Text] [Related]
56. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
57. The relationship between tumor markers and pulmonary embolism in lung cancer.
Xiong W; Zhao Y; Xu M; Guo J; Pudasaini B; Wu X; Liu J
Oncotarget; 2017 Jun; 8(25):41412-41421. PubMed ID: 28575869
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic value of CYFRA 21-1 and carcinoembryonic antigen in diagnosis of operable lung cancer from benign lung disease.
Chen F; Li J; Qi X; Qi J
J Cancer Res Ther; 2018 Jun; 14(Supplement):S400-S404. PubMed ID: 29970696
[TBL] [Abstract][Full Text] [Related]
59. Identifying high risk individuals for targeted lung cancer screening: Independent validation of the PLCO
Weber M; Yap S; Goldsbury D; Manners D; Tammemagi M; Marshall H; Brims F; McWilliams A; Fong K; Kang YJ; Caruana M; Banks E; Canfell K
Int J Cancer; 2017 Jul; 141(2):242-253. PubMed ID: 28249359
[TBL] [Abstract][Full Text] [Related]
60. Comparison of tumor markers and inflammatory biomarkers in chronic obstructive pulmonary disease (COPD) exacerbations.
Barouchos N; Papazafiropoulou A; Iacovidou N; Vrachnis N; Barouchos N; Armeniakou E; Dionyssopoulou V; Mathioudakis AG; Christopoulou E; Koltsida S; Bassiakou E
Scand J Clin Lab Invest; 2015 Apr; 75(2):126-32. PubMed ID: 25598350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
